SubHero Banner

Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) – New orphan drug approval

October 21, 2019 - The FDA announced the approval of Vertex’s Trikafta (elexacaftor/tezacaftor/ ivacaftor; ivacaftor), for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Download PDF